Core Insights - Inhibikase Therapeutics has successfully closed a private placement raising approximately $110 million, with potential total financing of up to $275 million through warrants, aimed at funding the Phase 2b trial for IkT-001Pro in Pulmonary Arterial Hypertension (PAH) and general corporate purposes [1][2] Company Overview - Inhibikase Therapeutics is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapeutics targeting cardiopulmonary and neurodegenerative diseases through Abelson Tyrosine Kinase inhibition [1][10] - The company’s lead product, IkT-001Pro, is a prodrug formulation of imatinib mesylate, designed to improve the safety profile of imatinib, which is used for various cancers and has shown potential benefits in PAH [7][10] Financial Highlights - The private placement financing will support the execution of the Phase 2b '702' trial for IkT-001Pro and other corporate needs [1][2] - The financing is considered transformational, reflecting the confidence of top-tier healthcare investment funds in the potential of IkT-001Pro to improve patient outcomes in PAH [2] Leadership Changes - Concurrent with the financing, Inhibikase appointed several experienced leaders in biopharmaceutical development to its Board of Directors, including Roberto Bellini, Amit Munshi, Arvind Kush, and David Canner [2][3] - Roberto Bellini has been appointed as the Independent Chairperson of the Board, bringing extensive experience from his previous role as CEO of BELLUS Health [3][4] Product Development - IkT-001Pro has shown in preclinical studies to be up to 3.4 times safer and better tolerated than imatinib, potentially reducing gastrointestinal and other side effects associated with oral administration [7] - The FDA has cleared the 702 trial for clinical entry at Phase 2b, and IkT-001Pro has received Orphan Drug Designation for Stable-Phase CML, with a similar designation currently under review for PAH [7]

-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or the "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the pricing of an approximately $110 ...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2024 Earnings Conference Call August 15, 2024 8:00 AM ET Company Participants Alexander Lobo - Precision AQ, Investor Relations Milton Werner - President and Chief Executive Officer Garth Lees-Rolfe - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group Edward White - H.C. Wainwright Operator Greetings and welcome to the Inhibikase Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time, all participants are ...

Core Viewpoint - Inhibikase Therapeutics, Inc. has reported its financial results for Q2 2024, highlighting advancements in its clinical pipeline, particularly for risvodetinib and IkT-001Pro, while also showing a reduction in net loss compared to the previous year [1][4]. Recent Developments and Upcoming Milestones - The company completed enrollment in the Phase 2 '201' trial for risvodetinib, with 126 patients enrolled and the last patient expected to exit the trial in September 2024, with topline data anticipated in November 2024 [2][3]. - IkT-001Pro has progressed as a potential treatment for Pulmonary Arterial Hypertension (PAH), with an IND filed and plans to ramp up the Phase 2 '702' trial following FDA clearance [2][3]. - The FDA acknowledged the company's bridging study between imatinib's use in cancers and PAH, deeming the Phase 2 design reasonable [3]. - The active ingredient in IkT-001Pro, imatinib, has shown potential as a disease-modifying agent for PAH, with a market value of $7.66 billion in 2023 for this indication [3]. - The company successfully raised $4 million in May 2024 to support the advancement of risvodetinib and IkT-001Pro [3]. Financial Results - The net loss for Q2 2024 was $5.0 million, or $0.66 per share, an improvement from a net loss of $5.8 million, or $0.94 per share in Q2 2023 [4]. - Research and development expenses decreased to $3.1 million in Q2 2024 from $4.5 million in Q2 2023, primarily due to the completion of a dose-finding study [5]. - Selling, general and administrative expenses increased to $2.0 million in Q2 2024 from $1.8 million in Q2 2023, driven by higher legal and consulting fees [6]. - As of June 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $7.9 million, expected to fund operations into December 2024 [7].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-3407249 ( State or other ju ...

BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Followi ...

BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Followi ...

BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the company has completed enrollment in the Phase 2 '201' trial evaluating the safety and tolerability of risvodetinib ("risvo"), a potent selective c-Ab ...

"The completion of enrollment for the 201 Trial in untreated Parkinson's disease represents a major milestone for Inhibikase," said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. "This achievement reflects the hard work of our team, the success of our proprietary and innovative patient identification and referral service and the commitment of our 32 U.S. study sites to evaluating potential diseasemodifying solutions for patients with this debilitating disease. With enrollment in ...

BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced expansion of its therapeutic pipeline and multiple updates to its Research and Development programs. "At Inhibikase we have let fundamental scientific ...